Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis

Fevipiprant is a non-steroidal oral prostaglandin D2 (PGD2) receptor 2 antagonist that reduces bronchial wall inflammation, possibly improving clinical outcomes in the asthmatic population. A systemic review search was conducted on PubMed, Embase, and Central Cochrane Registry. Randomized clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jahangir, Abdullah, Sattar, Saud Bin Abdul, Rafay Khan Niazi, Muhammad, Muhammad, Marwah, Jahangir, Ahmad, Sahra, Syeda, Sharif, Muhammad Ans, Anwar, Muhammad Yasir, Chalhoub, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Pulmonology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153206/
https://www.ncbi.nlm.nih.gov/pubmed/35663651
http://dx.doi.org/10.7759/cureus.24641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153206/
https://www.ncbi.nlm.nih.gov/pubmed/35663651
http://dx.doi.org/10.7759/cureus.24641

Ejemplares similares